© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia
Affiliations of authors: N. F. Schlecht, E. L. Franco (Departments of Oncology and Epidemiology and Biostatistics), R. W. Platt (Departments of Epidemiology and Biostatistics and Pediatrics), E. Duarte-Franco (Department of Oncology), McGill University, Montreal, Quebec, Canada; M. C. Costa, J. P. Sobrinho, J. C. M. Prado, L. L. Villa, Ludwig Institute for Cancer Research, São Paulo, Brazil; A. Ferenczy, Department of Pathology, McGill University; T. E. Rohan, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY.
Correspondence to: Eduardo L. Franco, PhD, Department of Oncology, McGill University, 546 Pine Ave. West, Montreal, Quebec, Canada H2W 1S6 (e-mail: eduardo.franco{at}mcgill.ca).
Background: Little is known about the duration of precancerous cervical lesions in relation to human papillomavirus (HPV) infection. We estimated rates of progression and regression and sojourn times of cervical squamous intraepithelial lesions (SILs) according to HPV status. Methods: We used data from a longitudinal study of HPV infection and cervical neoplasia in São Paulo, Brazil. Cervical specimens were taken from 2404 women for Pap cytology and polymerase chain reaction–based HPV testing every 4–6 months over a period of 8 years. We used actuarial and non-actuarial analyses to measure time to and rates of lesion progression and regression according to status and type of HPV infection. Results: During follow-up, 118 low-grade SIL (LSIL), 24 high-grade SIL (HSIL), and 173 atypical squamous cells of undetermined significance (ASCUS) events were detected. Mean time to progression from ASCUS to LSIL or worse and from LSIL to HSIL or worse was shorter in women with oncogenic HPV types than in women with no HPV infection (mean times for ASCUS progression were 67.0 and 88.0 months, respectively, in women with oncogenic HPV and no HPV, difference = 21.0 months, 95% confidence interval [CI] = 11.3 to 30.7 months; mean times for LSIL progression were 73.3 and 83.5 months, respectively, difference = 10.2 months, 95% CI = –0.15 to 20.6 months). Half of the LSILs regressed to normal or ASCUS within 6 months. Mean times for regression from ASCUS to normal, from LSIL to ASCUS or normal, and from HSIL/cervical intraepithelial neoplasia 2 to ASCUS or normal were longer for women with oncogenic HPV types (16.8 months, 95% CI = 7.5 to 26.2 months; 13.8 months, 95% CI = 8.8 to 18.7 months; and 17.1 months, 95% CI = 4.1 to 30.1 months, respectively) than for women with non-oncogenic HPV types (7.7 months, 95% CI = 5.2 to 10.2 months; 7.8 months, 95% CI = 5.3 to 10.2 months; 8.9 months, 95% CI = 3.3 to 14.6 months) or for women with no HPV infection (7.6 months, 95% CI = 6.9 to 8.4 months; 7.6 months, 95% CI = 6.4 to 8.7 months; and 7.0 months, 95% CI = 5.0 to 8.9 months, respectively). Conclusion: Precursor lesions of the cervix persist longer and progress more quickly in women with oncogenic HPV infections than in women with non-oncogenic infections or without HPV. Testing cervical lesions for oncogenic HPVs may help identify those that are likely to progress rapidly.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. J. Kim, J. Ortendahl, and S. J. Goldie Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States Ann Intern Med, October 20, 2009; 151(8): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Lepique, K. R. P. Daghastanli, I. M. Cuccovia, and L. L. Villa HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses Clin. Cancer Res., July 1, 2009; 15(13): 4391 - 4400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-H. Zahl, J. Maehlen, and H. G. Welch The Natural History of Invasive Breast Cancers Detected by Screening Mammography Arch Intern Med, November 24, 2008; 168(21): 2311 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pande, N. Jain, B. K. Prusty, S. Bhambhani, S. Gupta, R. Sharma, S. Batra, and B. C. Das Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Biopsy Samples from Cervical Cancer Patients in North India J. Clin. Microbiol., March 1, 2008; 46(3): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Van de Velde, M. Brisson, and M.-C. Boily Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty Am. J. Epidemiol., April 1, 2007; 165(7): 762 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dillon, T. Sasagawa, A. Crawford, J. Prestidge, M. K. Inder, J. Jerram, A. A. Mercer, and M. Hibma Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2 J. Gen. Virol., March 1, 2007; 88(3): 803 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lau and E. L. Franco Management of low-grade cervical lesions in young women Can. Med. Assoc. J., September 27, 2005; 173(7): 771 - 774. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dias, J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J. M. Antonello, T. Green, et al. Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 Clin. Vaccine Immunol., August 1, 2005; 12(8): 959 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Clifford, R. K. Rana, S. Franceschi, J. S. Smith, G. Gough, and J. M. Pimenta Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1157 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wallace, B. A. Woda, and G. Pihan Facile, Comprehensive, High-Throughput Genotyping of Human Genital Papillomaviruses Using Spectrally Addressable Liquid Bead Microarrays J. Mol. Diagn., February 1, 2005; 7(1): 72 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Preville, D. Ladant, B. Timmerman, and C. Leclerc Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein Cancer Res., January 15, 2005; 65(2): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Stewart and A. S. Coates Cancer Prevention: A Global Perspective J. Clin. Oncol., January 10, 2005; 23(2): 392 - 403. [Abstract] [Full Text] [PDF]
|
|